Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Neurogene Inc.AQXP · Entity 5160 | Director | May 07, 2018 | May 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Neurogene Inc.
Report date May 07, 2018 · Filed May 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.10 · Expires 2028-05-06 | Direct | 15,000 |
Reported balance
After 2018-05-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-07 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Sierra Oncology, Inc.
Report date July 01, 2022 · Filed July 01, 2022
Section 16 reporting ended · disclosed 2022-07-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $268.20 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Disposition to issuer · Disposed 671 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1: The option fully vested on June 18, 2016. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $82.40 · Expires 2026-06-16 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-07-01 · Disposition to issuer · Disposed 970 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3: The option fully vested on June 16, 2017. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.20 · Expires 2027-06-13 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-07-01 · Disposition to issuer · Disposed 625 · Balance 0 F5: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4: The option fully vested on June 13, 2018. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $130.80 · Expires 2028-06-12 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-07-01 · Disposition to issuer · Disposed 625 · Balance 0 F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6: The option fully vested on June 12, 2019. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.40 · Expires 2029-06-11 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-07-01 · Disposition to issuer · Disposed 750 · Balance 0 F5: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F7: The option fully vested on June 11, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-07-01 · Disposition to issuer · Disposed 16,686 · Balance 0 F5: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8: The option fully vested on June 9, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.11 · Expires 2031-06-08 | Direct | 0 |
Reported balance
After 2022-07-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-07-01 · Disposition to issuer · Disposed 6,000 · Balance 0 F5: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F9: The option fully vested on June 8, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option fully vested on June 18, 2016.
F2: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger.
F3: The option fully vested on June 16, 2017.
F4: The option fully vested on June 13, 2018.
F5: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price.
F6: The option fully vested on June 12, 2019.
F7: The option fully vested on June 11, 2020.
F8: The option fully vested on June 9, 2021.
F9: The option fully vested on June 8, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 7 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F5 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F9 · derivative.exercise_date: The option fully vested on June 8, 2022. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 16,686 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 6 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,686 shares Expires 2030-06-09 F5 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F8 · derivative.exercise_date: The option fully vested on June 9, 2021. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 750 | $0.00 Strike: $26.40 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 5 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires 2029-06-11 F5 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F7 · derivative.exercise_date: The option fully vested on June 11, 2020. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 625 | $0.00 Strike: $130.80 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 4 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires 2028-06-12 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F6 · derivative.exercise_date: The option fully vested on June 12, 2019. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 625 | $0.00 Strike: $45.20 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 3 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 625 shares Expires 2027-06-13 F5 · price: Pursuant to the terms of the merger agreement between issuer, GSK and a subsidiary of GSK, this option was cancelled on the effective date of the merger in exchange for a cash payment equal to, on a per share basis, the offer price of $55.00 less the exercise price. F4 · derivative.exercise_date: The option fully vested on June 13, 2018. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 970 | $0.00 Strike: $82.40 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 2 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 970 shares Expires 2026-06-16 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F3 · derivative.exercise_date: The option fully vested on June 16, 2017. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 16:41 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | Disposition to issuerStock Option (right to buy) · Derivative | 671 | $0.00 Strike: $268.20 | $0.00 |
DisclosureSEC source: 0001209191-22-040266 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 671 shares Expires 2025-06-17 F2 · price: Pursuant to the terms of the merger agreement between issuer, GlaxoSmithKline plc ("GSK") and a subsidiary of GSK, this option was cancelled on the effective date of the merger. F1 · derivative.exercise_date: The option fully vested on June 18, 2016. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 10:38 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (Right To Buy) · Derivative | 6,000 | $0.00 Strike: $18.11 | $0.00 |
DisclosureSEC source: 0001209191-21-039092 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The Option fully vests and becomes exercisable on June 8, 2022, subject to the Reporting Person's provision of service to the Issuer as of the vesting date. Read SEC document |
| June 09, 2020 Filed Jun 10, 2020 19:01 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 16,686 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-20-035690 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,686 Underlying: Common Stock · 16,686 shares Expires 2030-06-09 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 9, 2020, with 100% of the total shares vested and exercisable on June 9, 2021, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 17:55 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001209191-19-036491 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 17:10 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001209191-18-037790 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 12, 2018, with 100% of the total shares vested and exercisable on June 12, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:17 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $13.10 | $0.00 |
DisclosureSEC source: 0001209191-18-028983 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-06 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 7, 2018 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 17:31 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-17-039878 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 13, 2017, with 100% of the total shares vested and exercisable on June 13, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| May 08, 2017 Filed May 10, 2017 22:36 UTC | Neurogene Inc. AQXP · Entity 5160 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $13.74 | $0.00 |
DisclosureSEC source: 0001209191-17-031399 · doc4.xml · derivative · entry 1 Pelzer Robert · CIK 0001297500 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2027-05-07 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable at a rate of 1/12th of the total number of shares underlying the options on the one-month anniversary of May 8, 2017 (the "Vesting Commencement Date") and 1/12th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.